News | October 29, 2021
Laurus Labs PAT at Rs 201.90 cr. in Q2FY21
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The NFI is published to promote the rational use of medicines in the country.
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
It answers the most basic questions from a patient’s perspective
A total of 12 generic medicines have been included in the list
Subscribe To Our Newsletter & Stay Updated
